Skip to Main content Skip to Navigation
Journal articles

US Food and Drug Administration approval of esketamine and brexanolone

Abstract : In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).
Document type :
Journal articles
Complete list of metadatas

Cited literature [13 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02363651
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, February 18, 2020 - 10:32:49 AM
Last modification on : Thursday, June 18, 2020 - 9:29:11 AM
Long-term archiving on: : Tuesday, May 19, 2020 - 1:20:47 PM

File

Cristea_et al_2019_US FDA appr...
Files produced by the author(s)

Identifiers

Citation

Ioana A Cristea, Florian Naudet. US Food and Drug Administration approval of esketamine and brexanolone. The Lancet. Psychiatry, Elsevier, 2019, 6 (12), pp.975-977. ⟨10.1016/S2215-0366(19)30292-5⟩. ⟨hal-02363651⟩

Share

Metrics

Record views

137

Files downloads

219